About

Khloris Biosciences is a private biotechnology company located in the San Francisco Bay Area. We are dedicated to revolutionizing medical treatment and prevention of cancer and other diseases by harnessing the unlimited immunotherapeutic potential of induced pluripotent stem cells (iPSCs) for drug discovery, vaccine and cell therapies.

The unlimited potential of iPSCs
drug discovery
vaccine
cell therapy

technology

technology

arrow iPSC technologies have the potential to bring ground breaking transformations to future medical treatments.

Khloris has already shown that irradiated iPSCs can prevent tumor growth in murine models of breast, lung, and skin cancer and our data demonstrate that iPSC vaccines target shared antigens between iPSCs and cancer cells. Interestingly iPSC vaccines promote a humoral and cell-mediated anti-tumor immune profile and can work as an adjuvant cancer therapy and reactivate the immune system.

khloris technology vision

khloris technology vision

figure figure
svg
PROGRAMMING
of PBMCs1 into iPSCs2
numeration
svg
ENGINEERING
of iPSCs +/- tumor specific antigens or adjuvants
numeration
svg
VACCINATION with anti-cancer iPSCs
numeration
svg
PROTECTION against tumor
numeration

What we strive for

~4 weeks

What
we
strive
for
protection
PROTECTION
against tumor
programming
PROGRAMMING
of PMBC in iPSCs
main
vaccination
VACCINATION
with anti-cancer
iPSCs
engineering
ENGINEERING
of iPSCs +/- tumor specific
antigens or adjuvants
Khloris Biosciences aims to treat existing cancer patients and individuals with high risk of developing tumors (genetically linked cancers) with iPSCs vaccination.
Khloris Biosciences aims to treat existing cancer patients and individuals with high risk of developing tumors (genetically linked cancers) with iPSCs vaccination.

team

LYNNE A. BUI,
MD
JOSEPH C. WU, MD, PHD
JÜRGEN ECKHARDT, MD, MBA
LUCIO IANNONE, PHD
avatar
Lynne A. Bui, MD is the Co-Founder, President and CEO of Khloris Biosciences, Inc. She is a board-certified hematologist oncologist, seasoned entrepreneur, angel investor and drug developer, having unparalleled experience in basic, translational and clinical research spanning over 15 years with direct patient care and leading clinical development programs from preclinical IND enabling studies to Phase 1 to 3 registration studies for multiple approved drugs. She has held senior level positions at Exelixis, Onyx, and Intellikine, and has experience with small molecules, antibodies, dendritic cell vaccines, gene therapies, embryonic stem cells, and cell therapies. She is also the Founder and Chairman of Global Cancer Research Institute (GCRI) and GCRI Foundation. She received her M.D., internal medicine residency and hematology/oncology fellowship training from the David Geffen UCLA School of Medicine, and her B.A. in molecular and cellular biology with an emphasis in neurobiology from UC Berkeley.
avatar
Joseph C. Wu, MD, PhD is a Co-Founder and Director of Khloris Biosciences, Inc. He is the Director of the Stanford Cardiovascular Institute and a Professor of Medicine & Radiology at Stanford University School of Medicine. He is a board-certified cardiologist. Over the past 10 years, his lab has studied extensively on the application of iPSCs for cardiovascular disease modeling, drug discovery, and regenerative medicine. He has published over 300 peer-reviewed articles in these areas. He has received several prestigious awards and recognitions from the NIH and AHA, and was a recipient of the Presidential Early Career Award for Scientists and Engineers (PECASE) from the Obama administration. Dr. Wu received his M.D. from Yale University School of Medicine, his Ph.D., internal medicine residency and cardiology fellowship training from the David Geffen UCLA School of Medicine, and his B.A. in biology from UCLA.
avatar
Jürgen Eckhardt is Head of Leaps by Bayer, where he is responsible for all minority equity investments. Before joining Bayer, Jürgen Eckhardt was a venture capitalist for 14 years and head of the venture capital franchise at Bellevue/BB Biotech in Switzerland. He raised and invested several funds in biotech, medical devices, and healthcare services in Europe and the US. Jürgen Eckhardt previously worked for 8 years at McKinsey & Co. in Zürich and New York, where he was an Associate Partner and member of the Healthcare Leadership Team. He began his career as a radiologist at the University Hospital of Basel, Switzerland. He studied medicine and business; he received his M.D. from the University of Basel, Switzerland, in 1992, and his MBA from INSEAD in Fontainebleau, France, in 1996.
avatar
Lucio Iannone is Director Venture Investments of Leaps by Bayer, where he is responsible for developing investment cases and deal execution. He is also involved in sourcing, screening, and mentoring of companies with game-changing science. Before joining Bayer, Lucio Iannone had several senior roles in biotechnology companies and venture capital firms. He has experience with molecular biology, cell & gene therapy technologies and their application in oncology and other therapeutic fields. Lucio Iannone began his career as a cardiovascular scientist at Imperial college of London in the department of experimental medicine where he received his Ph.D.
LYNNE A. BUI,
MD
avatar
Lynne A. Bui, MD is the Co-Founder, President and CEO of Khloris Biosciences, Inc. She is a board-certified hematologist oncologist, seasoned entrepreneur, angel investor and drug developer, having unparalleled experience in basic, translational and clinical research spanning over 15 years with direct patient care and leading clinical development programs from preclinical IND enabling studies to Phase 1 to 3 registration studies for multiple approved drugs. She has held senior level positions at Exelixis, Onyx, and Intellikine, and has experience with small molecules, antibodies, dendritic cell vaccines, gene therapies, embryonic stem cells, and cell therapies. She is also the Founder and Chairman of Global Cancer Research Institute (GCRI) and GCRI Foundation. She received her M.D., internal medicine residency and hematology/oncology fellowship training from the David Geffen UCLA School of Medicine, and her B.A. in molecular and cellular biology with an emphasis in neurobiology from UC Berkeley.
JOSEPH C. WU, MD, PHD
avatar
Joseph C. Wu, MD, PhD is a Co-Founder and Director of Khloris Biosciences, Inc. He is the Director of the Stanford Cardiovascular Institute and a Professor of Medicine & Radiology at Stanford University School of Medicine. He is a board-certified cardiologist. Over the past 10 years, his lab has studied extensively on the application of iPSCs for cardiovascular disease modeling, drug discovery, and regenerative medicine. He has published over 300 peer-reviewed articles in these areas. He has received several prestigious awards and recognitions from the NIH and AHA, and was a recipient of the Presidential Early Career Award for Scientists and Engineers (PECASE) from the Obama administration. Dr. Wu received his M.D. from Yale University School of Medicine, his Ph.D., internal medicine residency and cardiology fellowship training from the David Geffen UCLA School of Medicine, and his B.A. in biology from UCLA.
JÜRGEN ECKHARDT, MD, MBA
avatar
Jürgen Eckhardt is Head of Leaps by Bayer, where he is responsible for all minority equity investments. Before joining Bayer, Jürgen Eckhardt was a venture capitalist for 14 years and head of the venture capital franchise at Bellevue/BB Biotech in Switzerland. He raised and invested several funds in biotech, medical devices, and healthcare services in Europe and the US. Jürgen Eckhardt previously worked for 8 years at McKinsey & Co. in Zürich and New York, where he was an Associate Partner and member of the Healthcare Leadership Team. He began his career as a radiologist at the University Hospital of Basel, Switzerland. He studied medicine and business; he received his M.D. from the University of Basel, Switzerland, in 1992, and his MBA from INSEAD in Fontainebleau, France, in 1996.
LUCIO IANNONE, PHD
avatar
Lucio Iannone is Director Venture Investments of Leaps by Bayer, where he is responsible for developing investment cases and deal execution. He is also involved in sourcing, screening, and mentoring of companies with game-changing science. Before joining Bayer, Lucio Iannone had several senior roles in biotechnology companies and venture capital firms. He has experience with molecular biology, cell & gene therapy technologies and their application in oncology and other therapeutic fields. Lucio Iannone began his career as a cardiovascular scientist at Imperial college of London in the department of experimental medicine where he received his Ph.D.

careers

careers

We are actively hiring. Khloris is always interested in knowing the best and the brightest talent. If you do not see a role that matches your background, we encourage you to email your resume to: careers@khlorisbiosciences.com

It will help us find you if a new need arises that fits your experience.